Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Hepatitis C virus Genotype 1 with detectable plasma hepatitis C virus RNA~* Have been infected with Hepatitis C virus for greater than (\>) 6 months~* Seronegative for hepatitis B surface antigen and human immunodeficiency virus 1 and 2~* Must agree to use 2 methods of contraception, including 1 barrier method, during and for 24 weeks after the completion of the study (unless the subject is a female of documented non-child-bearing potential)~* Female subjects must have a negative pregnancy test at all visits before the first dose.~Exclusion Criteria:~* Received any approved or investigational drug or drug regimen for the treatment of hepatitis C.~* Any medical contraindications to Peg-IFN-alfa-2a or Ribavirin therapy~* Any other cause of significant liver disease in addition to hepatitis C; this may include but is not limited to, hepatitis B, drug or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, Nonalcoholic Steatohepatitis or primary biliary cirrhosis.~* Diagnosed or suspected hepatocellular carcinoma.~* Histologic evidence of hepatic cirrhosis (including compensated cirrhosis) based on a liver biopsy taken within 2 years before Study start.~* Alcohol/drug abuse or excessive use in the last 12 months.~* Participation in any investigational drug study within 90 days before drug administration or participation in more than 2 drug studies in the last 12 months (exclusive of the current study).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week (Type: PLACEBO_COMPARATOR): Placebo (PBO) matched to telaprevir tablet orally thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (\<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (\>=) 75 kg, for 48 weeks.
- Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week (Type: EXPERIMENTAL): Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet orally thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 24 weeks.
- Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week (Type: EXPERIMENTAL): Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 12 weeks.
- Telaprevir 12 Week+Peg-IFN-alfa-2a 12 Week (Type: EXPERIMENTAL): Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection, for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).